Previous close | 400.35 |
Open | 396.54 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 393.25 - 399.62 |
52-week range | 290.87 - 446.29 |
Volume | |
Avg. volume | 2,907 |
Market cap | 1.022B |
Beta (5Y monthly) | 0.37 |
PE ratio (TTM) | 0.42 |
EPS (TTM) | 9.48 |
Earnings date | 06 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
LONDON, April 26, 2024--Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.
Biogen, Bristol Myers Squibb, Incyte and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.
Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $397.70, moving -0.76% from the previous trading session.